Agreement to acquire TESARO

On 3 December 2018 we announced our agreement to acquire TESARO, an oncology-focused company based in the US for approximately $5.1bn.

The proposed transaction will significantly strengthen our pharmaceutical business, accelerating the build of our pipeline and commercial capability in oncology.

Transformative potential from PARPs

Our strong belief is that PARP inhibitors are important medicines that have been under appreciated in terms of the impact they can have on cancer patients. PARP inhibitors have transformed the treatment of ovarian cancer and offer significant opportunities for use in the treatment of multiple cancer types.